We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche Recognizes med fusion as a Molecular Center of Excellence

By LabMedica International staff writers
Posted on 06 Jun 2012
Roche Diagnostics (Roche; Basel, Switzerland), a biotech company focused on research-based healthcare, has formed an alliance with med fusion LLC (Lewisville, Texas, USA), an integrated laboratory and clinical trials service organization, designating the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

Established in 2002, Roche's MCOE program allows noncompeting regional laboratories across the United States to collaborate and capitalize on molecular testing instruments in order to advance test methodologies and technology.

As a nationally recognized Roche MCOE, med fusion's molecular diagnostics laboratory will offer healthcare professionals and patients some of the latest and most advanced molecular technologies, including Roche's cobas 4800 BRAF V600 Mutation Test, a companion diagnostic that identifies patients who are eligible for treatment with the ZELBORAF (vemurafenib) drug for inoperable or metastatic melanoma, a deadly form of skin cancer. More...


"Roche is very pleased to welcome med fusion into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, molecular diagnostics, Roche Diagnostics Corporation. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine."

med fusion is one of 35 labs in the United States and 3 in Texas that have received this accolade. According to Dr. Thomas Lohmann, chief medical officer, med fusion, the partnership with Roche will help the company provide healthcare professionals and patients with improved diagnostic services.

"This relationship with Roche will help keep med fusion on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies," added Dr. Lohmann.

Roche is an industry leader in pharmaceuticals and diagnostics, providing a broad range of products and services for the early detection, prevention, diagnosis, and treatment of diseases.



Related Links:

Roche Diagnostics

med fusion


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automatic CLIA Analyzer
Shine i6000
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.